Fusimab

About Fusimab

Fusimab is a biotechnology venture originating from a development at Tel Aviv University, stewarded by Ramot, the university's technology transfer company. The company is centered around the proprietary 'inclonal' technology, an innovation conceived by Professor Itai Benhar. This platform is engineered to facilitate the efficient expression and folding of full-length antibodies within a bacterial culture system.

The core of Fusimab's business is the application of its platform to develop bi-specific antibodies and antibody-toxin fusion proteins for oncological treatments. By producing these complex therapeutic proteins in bacteria, the technology has the potential to accelerate the timelines for both drug discovery and manufacturing processes. Antibody-toxin fusion proteins, a key area of focus, are designed to act as targeted delivery systems, where an antibody directs a toxic enzyme to cancer cells. This approach aims to internalize the toxic enzyme into the tumor cell, triggering cell-death mechanisms while minimizing harm to healthy tissues.

The company operates within the cancer immunotherapy market, a sector that leverages the body's immune system to combat malignancies. Specifically, it is focused on monoclonal antibody therapies, which are lab-produced molecules that can mimic or enhance the immune system's natural response. These therapies are particularly relevant for treating hematological malignancies like multiple myeloma, where they can target specific proteins on cancer cells. Fusimab's business model is predicated on leveraging its unique production platform to create novel therapeutic candidates for further development and eventual commercialization, likely through partnerships or licensing agreements with larger pharmaceutical entities.